PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,

PD-L1 in malignant pleural effusions

Alex Soltermann

Department of Pathology and Molecular Pathology

Lung adenocarcinoma, cT2b, cN2, cM1a, stage 4

PET-CT: centrally necrotic tumor right upper lung lobe, pleural infiltration, pleura carcinosis, massive effusion with subtotal atelectasis and eventual lymph node metastases hilar ipsilateral and mediastinal

Effusion cytologies (2 samples): TTF1+ lung adenocarcinoma

Mol Path: KRAS p.G12C exon 2

ECOG status 0 (fully active, able to carry on all pre-disease performance)

→ Cisplatin/Pemetrexed

Pat 68 yrs, 50 pys, 10/2015

• E1L3N antibody on Leica Bond automat

• Weak membranous immunoreactivity in >10% of tumor cells

• Category 3

01/2016 PD-L1 IHC

German PD-L1 harmonization trial

Tonsil, E1L3N, 100x

Effusion 1, E1L3N, 100x, Cat. 5

Effusion 2, E1L3N, 100x

Tonsil, SP263, 100x

Effusion 1, SP263, 100x

Effusion 2, SP263, 100x

Tonsil, DAKO 22C3 on Ventana

Effusion 2, DAKO 22C3 on Ventana